Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Investing.com - Scotiabank (TSX:BNS) raised its price target on Guardant Health (NASDAQ:GH) to $60.00 from $57.00 on Thursday, while maintaining a Sector Outperform rating following the company’s second-quarter results. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $47 to $70.
The healthcare company beat expectations across the board in its Q2 2025 financial performance, prompting management to raise full-year revenue guidance to 24-25% growth year-over-year, up significantly from the initial 15-16% projection. This builds on the company’s impressive 28.2% revenue growth over the last twelve months, with a robust gross margin of 61.34%.
Guardant Health’s Therapy Selection portfolio, which includes the Guardant360 products, continues to show impressive strength, with the company building a stronger competitive position through its expanding Smart Liquid Biopsy applications and companion liquid biopsy opportunities. With a current ratio of 4.11, InvestingPro analysis shows the company maintains strong liquidity to support its growth initiatives.
The company’s Reveal minimal residual disease (MRD) test is gaining momentum following Medicare reimbursement for colorectal cancer surveillance earlier this year, with further reimbursement and indication expansions expected in the near term.
Guardant’s Shield blood-based colorectal cancer screening test is exceeding expectations in its first commercial year, with Scotiabank noting its multi-cancer detection capability offers a compelling screening platform strategy that differentiates it from competitors. The company, currently valued at $5.6 billion, has seen its stock surge 47.92% year-to-date despite being slightly overvalued according to InvestingPro’s Fair Value model.
In other recent news, Guardant Health Inc. reported impressive financial results for the second quarter of 2025. The company exceeded earnings expectations with an earnings per share (EPS) of -$0.44, significantly better than the projected -$0.72. This resulted in a positive surprise of 38.89%. Revenue for the quarter reached $232.1 million, surpassing the anticipated $211.27 million, marking a 9.86% revenue surprise. These results highlight a strong performance for Guardant Health, as the company managed to outperform analysts’ forecasts. The earnings announcement has been a focal point for investors, reflecting a positive sentiment in the market. The company’s ability to deliver better-than-expected financial results is a notable development for stakeholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.